Physician profile
Ryan J Abel
NPI 1437385770
$6,198.84
in general payments reported to CMS, 2019-2025
63 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.18 · 2020: $82.56 · 2021: $134 · 2022: $1,277 · 2023: $1,228 · 2024: $1,532 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,609.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $737.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $464.01 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $416.11 | 2022-2025 | |
| Daiichi Sankyo INC. | $293.11 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $292.96 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $266.94 | 2022-2025 | Tagrisso, Enhertu, Imfinzi |
| Seagen INC. | $255.80 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Genentech USA, INC. | $207.87 | 2021-2025 | Tecentriq, Polivy, Venclexta |
| Amgen INC. | $183.91 | 2022 | |
| Novocure INC. | $183.11 | 2019-2025 | Optune, Optune Gio, Optune Lua (Novottf-200t) |
| Takeda Pharmaceuticals U.S.A., INC. | $170.52 | 2022-2025 | Iclusig, Fruzaqla, Ninlaro |
| Incyte Corporation | $160.02 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $150.26 | 2022-2025 | |
| Tempus Ai, INC | $141.51 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $138.38 | 2021-2025 | Libtayo |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.